건강 보도자료
-
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
- Takeda (TSE:4502/NYSE:TAK ) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adu...
- 01월 06일 09:04
-
- SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corp...
- 01월 05일 09:06
-
- Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Li...
- 01월 05일 08:54
